Skip to main content
Top
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

NBPF1, a tumor suppressor candidate in neuroblastoma, exerts growth inhibitory effects by inducing a G1 cell cycle arrest

Authors: Vanessa Andries, Karl Vandepoele, Katrien Staes, Geert Berx, Pieter Bogaert, Gert Van Isterdael, Daisy Ginneberge, Eef Parthoens, Jonathan Vandenbussche, Kris Gevaert, Frans van Roy

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

NBPF1 (Neuroblastoma Breakpoint Family, member 1) was originally identified in a neuroblastoma patient on the basis of its disruption by a chromosomal translocation t(1;17)(p36.2;q11.2). Considering this genetic defect and the frequent genomic alterations of the NBPF1 locus in several cancer types, we hypothesized that NBPF1 is a tumor suppressor. Decreased expression of NBPF1 in neuroblastoma cell lines with loss of 1p36 heterozygosity and the marked decrease of anchorage-independent clonal growth of DLD1 colorectal carcinoma cells with induced NBPF1 expression further suggest that NBPF1 functions as tumor suppressor. However, little is known about the mechanisms involved.

Methods

Expression of NBPF was analyzed in human skin and human cervix by immunohistochemistry. The effects of NBPF1 on the cell cycle were evaluated by flow cytometry. We investigated by real-time quantitative RT-PCR the expression profile of a panel of genes important in cell cycle regulation. Protein levels of CDKN1A-encoded p21CIP1/WAF1 were determined by western blotting and the importance of p53 was shown by immunofluorescence and by a loss-of-function approach. LC-MS/MS analysis was used to investigate the proteome of DLD1 colon cancer cells with induced NBPF1 expression. Possible biological interactions between the differentially regulated proteins were investigated with the Ingenuity Pathway Analysis tool.

Results

We show that NBPF is expressed in the non-proliferative suprabasal layers of squamous stratified epithelia of human skin and cervix. Forced expression of NBPF1 in HEK293T cells resulted in a G1 cell cycle arrest that was accompanied by upregulation of the cyclin-dependent kinase inhibitor p21CIP1/WAF1 in a p53-dependent manner. Additionally, forced expression of NBPF1 in two p53-mutant neuroblastoma cell lines also resulted in a G1 cell cycle arrest and CDKN1A upregulation. However, CDKN1A upregulation by NBPF1 was not observed in the DLD1 cells, which demonstrates that NBPF1 exerts cell-specific effects. In addition, proteome analysis of NBPF1-overexpressing DLD1 cells identified 32 differentially expressed proteins, of which several are implicated in carcinogenesis.

Conclusions

We demonstrated that NBPF1 exerts different tumor suppressive effects, depending on the cell line analyzed, and provide new clues into the molecular mechanism of the enigmatic NBPF proteins.
Appendix
Available only for authorised users
Literature
1.
go back to reference Laureys G, Speleman F, Opdenakker G, Benoit Y, Leroy J. Constitutional translocation t(1;17)(p36;q12-21) in a patient with neuroblastoma. Genes Chromosomes Cancer. 1990;2:252–4.CrossRefPubMed Laureys G, Speleman F, Opdenakker G, Benoit Y, Leroy J. Constitutional translocation t(1;17)(p36;q12-21) in a patient with neuroblastoma. Genes Chromosomes Cancer. 1990;2:252–4.CrossRefPubMed
2.
go back to reference Laureys G, Speleman F, Versteeg R, van der Drift P, Chan A, Leroy J, et al. Constitutional translocation t(1;17)(p36.31-p36.13;q11.2-q12.1) in a neuroblastoma patient. Establishment of somatic cell hybrids and identification of PND/A12M2 on chromosome 1 and NF1/SCYA7 on chromosome 17 as breakpoint flanking single copy markers. Oncogene. 1995;10:1087–93.PubMed Laureys G, Speleman F, Versteeg R, van der Drift P, Chan A, Leroy J, et al. Constitutional translocation t(1;17)(p36.31-p36.13;q11.2-q12.1) in a neuroblastoma patient. Establishment of somatic cell hybrids and identification of PND/A12M2 on chromosome 1 and NF1/SCYA7 on chromosome 17 as breakpoint flanking single copy markers. Oncogene. 1995;10:1087–93.PubMed
3.
go back to reference Vandepoele K, Andries V, Van Roy N, Staes K, Vandesompele J, Laureys G, et al. A constitutional translocation t(1;17)(p36.2;q11.2) in a neuroblastoma patient disrupts the human NBPF1 and ACCN1 genes (p. 1–12). PLoS One. 2008;3, e2207.CrossRefPubMedPubMedCentral Vandepoele K, Andries V, Van Roy N, Staes K, Vandesompele J, Laureys G, et al. A constitutional translocation t(1;17)(p36.2;q11.2) in a neuroblastoma patient disrupts the human NBPF1 and ACCN1 genes (p. 1–12). PLoS One. 2008;3, e2207.CrossRefPubMedPubMedCentral
4.
go back to reference Vandepoele K, Van Roy N, Staes K, Speleman F, van Roy F. A novel gene family NBPF: Intricate structure generated by gene duplications during primate evolution. Mol Biol Evol. 2005;22:2265–74.CrossRefPubMed Vandepoele K, Van Roy N, Staes K, Speleman F, van Roy F. A novel gene family NBPF: Intricate structure generated by gene duplications during primate evolution. Mol Biol Evol. 2005;22:2265–74.CrossRefPubMed
5.
go back to reference Popesco MC, Maclaren EJ, Hopkins J, Dumas L, Cox M, Meltesen L, et al. Human lineage-specific amplification, selection, and neuronal expression of DUF1220 domains. Science. 2006;313:1304–7.CrossRefPubMed Popesco MC, Maclaren EJ, Hopkins J, Dumas L, Cox M, Meltesen L, et al. Human lineage-specific amplification, selection, and neuronal expression of DUF1220 domains. Science. 2006;313:1304–7.CrossRefPubMed
6.
go back to reference O’Bleness MS, Dickens CM, Dumas LJ, Kehrer-Sawatzki H, Wyckoff GJ, Sikela JM. Evolutionary history and genome organization of DUF1220 protein domains. G3 (Bethesda). 2012;2:977–86.CrossRef O’Bleness MS, Dickens CM, Dumas LJ, Kehrer-Sawatzki H, Wyckoff GJ, Sikela JM. Evolutionary history and genome organization of DUF1220 protein domains. G3 (Bethesda). 2012;2:977–86.CrossRef
7.
go back to reference Andries V, Vandepoele K, van Roy F. The NBPF Gene Family. In: Shimada H, editor. Neuroblastoma-Present and Future. Rijeka, Croatia: InTech; 2012. p. 185–214. Andries V, Vandepoele K, van Roy F. The NBPF Gene Family. In: Shimada H, editor. Neuroblastoma-Present and Future. Rijeka, Croatia: InTech; 2012. p. 185–214.
8.
go back to reference Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol. 1999;17:2264–79.PubMed Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol. 1999;17:2264–79.PubMed
9.
go back to reference Oberthuer A, Theissen J, Westermann F, Hero B, Fischer M. Molecular characterization and classification of neuroblastoma. Future Oncol. 2009;5:625–39.CrossRefPubMed Oberthuer A, Theissen J, Westermann F, Hero B, Fischer M. Molecular characterization and classification of neuroblastoma. Future Oncol. 2009;5:625–39.CrossRefPubMed
10.
go back to reference Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, Bosse K, et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature. 2009;459:987–91.CrossRefPubMedPubMedCentral Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, Bosse K, et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature. 2009;459:987–91.CrossRefPubMedPubMedCentral
12.
go back to reference Van Maerken T, Rihani A, Dreidax D, De Clercq S, Yigit N, Marine JC, et al. Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol Cancer Ther. 2011;10:983–93.CrossRefPubMed Van Maerken T, Rihani A, Dreidax D, De Clercq S, Yigit N, Marine JC, et al. Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol Cancer Ther. 2011;10:983–93.CrossRefPubMed
13.
go back to reference Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:0034.1–11.CrossRef Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:0034.1–11.CrossRef
14.
go back to reference Kaur P. Interfollicular epidermal stem cells: identification, challenges, potential. J Invest Dermatol. 2006;126:1450–8.CrossRefPubMed Kaur P. Interfollicular epidermal stem cells: identification, challenges, potential. J Invest Dermatol. 2006;126:1450–8.CrossRefPubMed
17.
go back to reference Ghesquiere B, Jonckheere V, Colaert N, Van Durme J, Timmerman E, Goethals M, et al. Redox proteomics of protein-bound methionine oxidation. Mol Cell Proteomics. 2011;10:M110 006866.CrossRefPubMedPubMedCentral Ghesquiere B, Jonckheere V, Colaert N, Van Durme J, Timmerman E, Goethals M, et al. Redox proteomics of protein-bound methionine oxidation. Mol Cell Proteomics. 2011;10:M110 006866.CrossRefPubMedPubMedCentral
18.
go back to reference Colaert N, Helsens K, Impens F, Vandekerckhove J, Gevaert K. Rover: a tool to visualize and validate quantitative proteomics data from different sources. Proteomics. 2010;10:1226–9.CrossRefPubMed Colaert N, Helsens K, Impens F, Vandekerckhove J, Gevaert K. Rover: a tool to visualize and validate quantitative proteomics data from different sources. Proteomics. 2010;10:1226–9.CrossRefPubMed
19.
go back to reference el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817–25.CrossRefPubMed el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817–25.CrossRefPubMed
20.
go back to reference Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995;55:5187–90.PubMed Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995;55:5187–90.PubMed
22.
go back to reference Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, et al. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene. 1997;15:2767–72.CrossRefPubMed Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, et al. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene. 1997;15:2767–72.CrossRefPubMed
23.
go back to reference Anderson CW, Appella E, Sakaguchi K. Posttranslational modifications involved in the DNA damage response. J Protein Chem. 1998;17:527.PubMed Anderson CW, Appella E, Sakaguchi K. Posttranslational modifications involved in the DNA damage response. J Protein Chem. 1998;17:527.PubMed
24.
go back to reference Joseph P, O’Kernick CM, Othumpangat S, Lei YX, Yuan BZ, Ong TM. Expression profile of eukaryotic translation factors in human cancer tissues and cell lines. Mol Carcinog. 2004;40:171–9.CrossRefPubMed Joseph P, O’Kernick CM, Othumpangat S, Lei YX, Yuan BZ, Ong TM. Expression profile of eukaryotic translation factors in human cancer tissues and cell lines. Mol Carcinog. 2004;40:171–9.CrossRefPubMed
25.
go back to reference Ha SA, Shin SM, Namkoong H, Lee H, Cho GW, Hur SY, et al. Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis. Clin Cancer Res. 2004;10:8386–95.CrossRefPubMed Ha SA, Shin SM, Namkoong H, Lee H, Cho GW, Hur SY, et al. Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis. Clin Cancer Res. 2004;10:8386–95.CrossRefPubMed
26.
go back to reference Reddig PJ, Juliano RL. Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev. 2005;24:425–39.CrossRefPubMed Reddig PJ, Juliano RL. Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev. 2005;24:425–39.CrossRefPubMed
27.
go back to reference Yamamoto S, Tomita Y, Hoshida Y, Sakon M, Kameyama M, Imaoka S, et al. Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis. Clin Cancer Res. 2004;10:651–7.CrossRefPubMed Yamamoto S, Tomita Y, Hoshida Y, Sakon M, Kameyama M, Imaoka S, et al. Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis. Clin Cancer Res. 2004;10:651–7.CrossRefPubMed
28.
go back to reference Arumugam T, Logsdon CD. S100P: a novel therapeutic target for cancer. Amino Acids. 2011;41:893–9.CrossRefPubMed Arumugam T, Logsdon CD. S100P: a novel therapeutic target for cancer. Amino Acids. 2011;41:893–9.CrossRefPubMed
29.
go back to reference Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, et al. Functional evidence implicating S100P in prostate cancer progression. Int J Cancer. 2008;123:330–9.CrossRefPubMed Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, et al. Functional evidence implicating S100P in prostate cancer progression. Int J Cancer. 2008;123:330–9.CrossRefPubMed
Metadata
Title
NBPF1, a tumor suppressor candidate in neuroblastoma, exerts growth inhibitory effects by inducing a G1 cell cycle arrest
Authors
Vanessa Andries
Karl Vandepoele
Katrien Staes
Geert Berx
Pieter Bogaert
Gert Van Isterdael
Daisy Ginneberge
Eef Parthoens
Jonathan Vandenbussche
Kris Gevaert
Frans van Roy
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1408-5

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine